Metrinelle 2 mg Tablets.
PDF Leaflet Revision Date: 21 January 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Long-term treatment of endometriosis.
Dosage (summary)
1 tablet daily, starting on day 1 of the menstrual cycle.
Special Populations
- Renal impairment
- Hepatic impairment
- Adolescents (12-18 years)
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding.
Key Drug Interactions
- CYP3A4 inducers (e.g., rifampicin)
- CYP3A4 inhibitors (e.g., ketoconazole)
Contraindications
- Hypersensitivity to dienogest
- Severe hepatic disease
- Arterial and cardiovascular diseases
- Diabetes with vascular involvement
- Undiagnosed vaginal bleeding
- History of venous thromboembolic disorder
Common side effects
- Headache
- Breast discomfort
- Depressed mood
- Acne
- Nausea
Counselling Points
- Take at the same time daily
- Report mood changes or depressive symptoms
- Use non-hormonal contraception if needed
Serious warnings
- Increased risk of breast cancer with prolonged use
- Risk of thromboembolism
- Bone mineral density decrease in adolescents
Important Disclaimer
The Metrinelle 2 mg Tablets. professional information leaflet below is the property of Pharma Dynamics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
